Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications

被引：17

作者：

Del Principe, Maria Ilaria ^{[1
]}

Buccisano, Francesco ^{[1
]}

Maurillo, Luca ^{[1
]}

Sconocchia, Giuseppe ^{[2
]}

Cefalo, Mariagiovanna ^{[1
]}

Consalvo, Maria Irno ^{[1
]}

Sarlo, Chiara ^{[3
]}

Conti, Consuelo ^{[1
]}

De Santis, Giovanna ^{[1
]}

De Bellis, Eleonora ^{[1
]}

Di Veroli, Ambra ^{[1
]}

Palomba, Patrizia ^{[1
]}

Attrotto, Cristina ^{[1
]}

Zizzari, Annagiulia ^{[1
]}

Paterno, Giovangiacinto ^{[1
]}

Voso, Maria Teresa ^{[1
]}

Del Poeta, Giovanni ^{[1
]}

Lo-Coco, Francesco ^{[1
,4
]}

Arcese, William ^{[1
]}

Amadori, Sergio ^{[1
]}

Venditti, Adriano ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Ematol, Dipartimento Biomed & Prevenz, Rome, Italy

[2] CNR, Ist Farmacol Translaz, Dipartimento Med, Rome, Italy

[3] Policlin Univ Campus Biomed, Ematol, Rome, Italy

[4] IRCCS Fdn S Lucia, Lab Neurooncoematol, Rome, Italy

来源：

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES | 2016年 / 8卷

关键词：

MULTIPARAMETER FLOW-CYTOMETRY; STEM-CELL TRANSPLANTATION; BLOOD BLAST CLEARANCE; COMPLETE REMISSION; PERIPHERAL-BLOOD; AML PATIENTS; BONE-MARROW; RISK STRATIFICATION; INDUCTION THERAPY; DNMT3A MUTATIONS;

D O I：

10.4084/MJHID.2016.052

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients' risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.

引用

页数：13

共 96 条

[81] Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia [J].

Venditti, A ;

Buccisano, F ;

Del Poeta, G ;

Maurillo, L ;

Tamburini, A ;

Cox, C ;

Battaglia, A ;

Catalano, G ;

Del Moro, B ;

Cudillo, L ;

Postorino, M ;

Masi, M ;

Amadori, S .

BLOOD, 2000, 96 (12) :3948-3952

[82] Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings [J].

Voskova, D ;

Schoch, C ;

Schnittger, S ;

Hiddemann, W ;

Haferlach, T ;

Kern, W .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2004, 62B (01) :25-38

[83] Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation [J].

Walter, R. B. ;

Gyurkocza, B. ;

Storer, B. E. ;

Godwin, C. D. ;

Pagel, J. M. ;

Buckley, S. A. ;

Sorror, M. L. ;

Wood, B. L. ;

Storb, R. ;

Appelbaum, F. R. ;

Sandmaier, B. M. .

LEUKEMIA, 2015, 29 (01) :137-144

[84] Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy? [J].

Walter, Roland B. .

CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) :102-107

[85] Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission [J].

Walter, Roland B. ;

Buckley, Sarah A. ;

Pagel, John M. ;

Wood, Brent L. ;

Storer, Barry E. ;

Sandmaier, Brenda M. ;

Fang, Min ;

Gyurkocza, Boglarka ;

Delaney, Colleen ;

Radich, Jerald P. ;

Estey, Elihu H. ;

Appelbaum, Frederick R. .

BLOOD, 2013, 122 (10) :1813-1821

[86] Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies [J].

Will, Britta ;

Steidl, Ulrich .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (03) :391-401

[87] Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia [J].

Yan, Xiao-Jing ;

Xu, Jie ;

Gu, Zhao-Hui ;

Pan, Chun-Ming ;

Lu, Gang ;

Shen, Yang ;

Shi, Jing-Yi ;

Zhu, Yong-Mei ;

Tang, Lin ;

Zhang, Xiao-Wei ;

Liang, Wen-Xue ;

Mi, Jian-Qing ;

Song, Huai-Dong ;

Li, Ke-Qin ;

Chen, Zhu ;

Chen, Sai-Juan .

NATURE GENETICS, 2011, 43 (04) :309-U51

[88] Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial [J].

Yin, John A. Liu ;

O'Brien, Michelle A. ;

Hills, Robert K. ;

Daly, Sarah B. ;

Wheatley, Keith ;

Burnett, Alan K. .

BLOOD, 2012, 120 (14) :2826-2835

[89] Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia [J].

Zeijlemaker, W. ;

Kelder, A. ;

Oussoren-Brockhoff, Y. J. M. ;

Scholten, W. J. ;

Snel, A. N. ;

Veldhuizen, D. ;

Cloos, J. ;

Ossenkoppele, G. J. ;

Schuurhuis, G. J. .

LEUKEMIA, 2016, 30 (03) :708-715

[90] A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia [J].